CL2011000252A1 - Uso de estriol para preparar un medicamento util en la prevencion y/o el tratamiento de atrofia urogenital en mujeres. - Google Patents

Uso de estriol para preparar un medicamento util en la prevencion y/o el tratamiento de atrofia urogenital en mujeres.

Info

Publication number
CL2011000252A1
CL2011000252A1 CL2011000252A CL2011000252A CL2011000252A1 CL 2011000252 A1 CL2011000252 A1 CL 2011000252A1 CL 2011000252 A CL2011000252 A CL 2011000252A CL 2011000252 A CL2011000252 A CL 2011000252A CL 2011000252 A1 CL2011000252 A1 CL 2011000252A1
Authority
CL
Chile
Prior art keywords
estriol
women
prevention
prepare
treatment
Prior art date
Application number
CL2011000252A
Other languages
English (en)
Inventor
Fernandez Alvaro Acebron
Lousame Dolores Blanco
Del Prado Jaime Moscoso
Magro Concepcion Nieto
Original Assignee
Italfarmaco Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41012001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000252(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Italfarmaco Sa filed Critical Italfarmaco Sa
Publication of CL2011000252A1 publication Critical patent/CL2011000252A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de estriol para preparar una formulación farmacéutica de administración vaginal, capaz de autolimitar la absorción de estriol, útil para la prevención y/o el tratamiento de atrofia urogenital en mujeres con alta probabilidad de desarrollar un tumor estrógeno-dependiente o que padecen o han padecido un tumor estrógeno-dependiente.
CL2011000252A 2008-08-07 2011-02-04 Uso de estriol para preparar un medicamento util en la prevencion y/o el tratamiento de atrofia urogenital en mujeres. CL2011000252A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200802384A ES2344673B1 (es) 2008-08-07 2008-08-07 Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.

Publications (1)

Publication Number Publication Date
CL2011000252A1 true CL2011000252A1 (es) 2011-11-18

Family

ID=41012001

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000252A CL2011000252A1 (es) 2008-08-07 2011-02-04 Uso de estriol para preparar un medicamento util en la prevencion y/o el tratamiento de atrofia urogenital en mujeres.

Country Status (22)

Country Link
US (1) US9114143B2 (es)
EP (1) EP2328589B1 (es)
JP (1) JP6207118B2 (es)
KR (1) KR101790652B1 (es)
CN (1) CN102170886A (es)
BR (1) BRPI0917265A2 (es)
CA (1) CA2732877C (es)
CL (1) CL2011000252A1 (es)
CO (1) CO6351732A2 (es)
CY (1) CY1120962T1 (es)
DK (1) DK2328589T3 (es)
ES (2) ES2344673B1 (es)
HR (1) HRP20182020T1 (es)
HU (1) HUE041377T2 (es)
LT (1) LT2328589T (es)
MX (1) MX336154B (es)
PE (1) PE20110682A1 (es)
PL (1) PL2328589T3 (es)
PT (1) PT2328589T (es)
RU (1) RU2504381C2 (es)
SI (1) SI2328589T1 (es)
WO (1) WO2010015718A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3787633A1 (en) * 2018-05-02 2021-03-10 Pantarhei Oncology B.V. Treatment of advanced estrogen receptor positive breast cancer
CN110151680A (zh) * 2019-04-10 2019-08-23 重庆医药高等专科学校 雌三醇凝胶产品及制备方法
CN114588252A (zh) * 2022-04-08 2022-06-07 暨南大学附属第一医院（广州华侨医院） 一种用于缓解阴道萎缩和干燥症的组合物及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1866M (fr) 1961-04-07 1963-06-17 Vismara Francesco Spa Nouveaux éthers des hormones oestrogenes.
US4436738A (en) * 1982-03-15 1984-03-13 Mead Johnson & Company Stabilized estradiol cream composition
ATE151286T1 (de) 1983-11-14 1997-04-15 Columbia Lab Inc Bioadhäsive mittel
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
EP0452334A4 (en) 1989-10-31 1991-12-11 Watson Laboratoires, Inc. Mucoadhesive carrier for delivery of therapeutical agent
DE69014081T2 (de) 1989-10-31 1995-03-30 Columbia Laboratories, Inc., Miami, Fla. Mittel zur Feuchthaltung vaginalen Gewebes.
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
IL110024A (en) * 1994-06-15 1998-04-05 Yissum Res Dev Co Controlled release oral drug delivery system containing hydrogel- forming polymer
US5667492A (en) 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
AT408067B (de) 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
US5741525A (en) 1995-10-24 1998-04-21 Marshall University Research Corporation Vaginal pharmaceutical hydrogen peroxide composition
IT1275816B1 (it) 1995-10-27 1997-10-17 Montefarmaco Spa Composizioni farmaceutiche solide per uso vaginale
AU714797B2 (en) 1996-06-14 2000-01-13 Mcneil-Ppc, Inc. Moisture containing compositions that are spreadable onto and adherable to biomembranes, methods of making and use thereof
IT1284874B1 (it) 1996-08-02 1998-05-22 Farmigea Spa Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
ATE442844T1 (de) 1996-11-14 2009-10-15 Lipomedica Ehf Topische zusammensetzungen enthaltend als therapeutisch aktiven wirkstoff ein monoglycerid zur behandlung von schleimhautinfektionen
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6159491A (en) 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
ATE481108T1 (de) 1999-02-26 2010-10-15 Novartis Vaccines & Diagnostic Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
CA2386422A1 (en) 1999-10-22 2001-04-26 Lif-Hlaup Ehf. Bio-Gels Pharmaceuticals Inc. Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion
ATE355854T1 (de) 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US7709026B2 (en) 2001-10-29 2010-05-04 Columbia Laboratories, Inc. Low concentration of peroxide for treating or preventing vaginal infections
TWI336627B (en) * 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
ES2237298B1 (es) * 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
AR056453A1 (es) * 2005-08-12 2007-10-10 Drug Tech Corp Composiciones con estrogeno y metodos terapeuticos para su uso
EP1890704A1 (en) * 2005-12-16 2008-02-27 Lyle Corporate Development, Inc. Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen
EP2289486A1 (en) * 2005-12-27 2011-03-02 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
US20070264309A1 (en) * 2006-01-20 2007-11-15 Chollet Janet A Method Of Treating Atrophic Vaginitis
EP1872775A1 (en) 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
WO2008089405A1 (en) 2007-01-19 2008-07-24 Neurosci, Inc. Composition of multiple hormones delivered vaginally in a single cream
ES2310968B1 (es) * 2007-06-25 2010-02-08 Italfarmaco, S.A. Uso de estriol en bajas dosis.

Also Published As

Publication number Publication date
BRPI0917265A2 (pt) 2015-11-10
PL2328589T3 (pl) 2019-05-31
CY1120962T1 (el) 2019-12-11
WO2010015718A1 (en) 2010-02-11
DK2328589T3 (en) 2018-12-10
HRP20182020T1 (hr) 2019-01-25
MX2011001382A (es) 2011-03-29
LT2328589T (lt) 2019-01-10
US20110183950A1 (en) 2011-07-28
CA2732877A1 (en) 2010-02-11
HUE041377T2 (hu) 2019-05-28
EP2328589A1 (en) 2011-06-08
MX336154B (es) 2016-01-11
PE20110682A1 (es) 2011-09-28
SI2328589T1 (sl) 2019-02-28
ES2344673A1 (es) 2010-09-02
JP2011529951A (ja) 2011-12-15
PT2328589T (pt) 2018-12-18
KR101790652B1 (ko) 2017-11-20
US9114143B2 (en) 2015-08-25
RU2504381C2 (ru) 2014-01-20
ES2344673B1 (es) 2011-05-03
CO6351732A2 (es) 2011-12-20
EP2328589B1 (en) 2018-09-19
CN102170886A (zh) 2011-08-31
KR20110045041A (ko) 2011-05-03
JP6207118B2 (ja) 2017-10-04
ES2700614T3 (es) 2019-02-18
CA2732877C (en) 2017-04-18
RU2011108548A (ru) 2012-09-20

Similar Documents

Publication Publication Date Title
CY1120879T1 (el) Πολλαπλου συστατικου βιοδραστικος ενδοκολπικος δακτυλιος
CL2017000829A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino.
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
ECSP099826A (es) Uso de estriol en bajas dosis
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
PA8631801A1 (es) Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos
CL2012002326A1 (es) Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana.
CL2008003122A1 (es) Uso de un anticuerpo anti-cd20 de tipo ii util para preparar un medicamento para tratar un cancer que expresa cd20 en combinacion con un inhibidor de proteasoma, composicion farmaceutica que contiene dicha combinacion y kit del mismo
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
DOP2013000224A (es) Uso de 2,3-dihidroimidazo[1,2-c] quinazolinas sustituidas.
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
CL2011002962A1 (es) Uso de al menos un ligando especifico de integrina para el tratamiento de cancer, y donde el medicamento es para ser usado en combinacion con al menos un agente adicional seleccionado de a) uno o mas agentes alquilantes y b) uno o mas agentes quimioterapeuticos diferente a los anteriores.
CL2007000345A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes.
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
PE20081881A1 (es) Agentes terapeuticos para canceres resistentes a agentes quimioterapicos que incluyen como ingrediente activo un anticuerpo que reconoce hla de clase i y sus usos
BR112013010829A2 (pt) composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma
BR112012022243A8 (pt) Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico
BRPI0513938B8 (pt) composição farmacêutica contendo drospirenona e etinilestradiol
NO20091628L (no) Kombinasjonsmedikament
CL2011000252A1 (es) Uso de estriol para preparar un medicamento util en la prevencion y/o el tratamiento de atrofia urogenital en mujeres.
UA108993C2 (en) MEDICINAL COMBINATION WITH THEOBROMINE AND ITS APPLICATION IN Cough
AR052048A1 (es) Composiciones farmaceuticas para el tratamiento de la celulitis
ECSP12012132A (es) Combinación de teobromina con un descongestivo y su uso para el tratamiento de la tos